2.29
1.78%
+0.04
TherapeuticsMD Inc stock is currently priced at $2.29, with a 24-hour trading volume of 9,827.
It has seen a +1.78% increased in the last 24 hours and a -3.38% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.25 pivot point. If it approaches the $2.30 resistance level, significant changes may occur.
TherapeuticsMD Inc Stock (TXMD) Financials Data
TherapeuticsMD Inc (TXMD) Revenue 2023
TXMD reported a revenue (TTM) of $69.37 million for the quarter ending September 30, 2023, a +207.87% rise year-over-year.
TherapeuticsMD Inc (TXMD) Net Income 2023
TXMD net income (TTM) was $68.31 million for the quarter ending September 30, 2023, a +888.31% increase year-over-year.
TherapeuticsMD Inc (TXMD) Cash Flow 2023
TXMD recorded a free cash flow (TTM) of -$1.32 million for the quarter ending September 30, 2023, a +97.88% increase year-over-year.
TherapeuticsMD Inc (TXMD) Earnings per Share 2023
TXMD earnings per share (TTM) was $7.17 for the quarter ending September 30, 2023, a +817.00% growth year-over-year.
TherapeuticsMD Inc Stock (TXMD) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Walker Marlan D | Chief Executive Officer |
Dec 06 '23 |
Sale |
2.31 |
14,500 |
33,496 |
67,115 |
Walker Marlan D | Chief Executive Officer |
Dec 05 '23 |
Option Exercise |
0.00 |
70,000 |
0 |
81,615 |
Walker Marlan D | Chief Executive Officer |
Apr 12 '23 |
Option Exercise |
0.00 |
7,508 |
0 |
13,477 |
Donegan Michael C | Prin. Fin. and Acctg. Officer |
Apr 12 '23 |
Option Exercise |
0.00 |
50,000 |
0 |
61,853 |
Walker Marlan D | Chief Executive Officer |
Apr 12 '23 |
Sale |
3.65 |
1,170 |
4,276 |
12,307 |
TherapeuticsMD Inc Stock (TXMD) Latest News
About TherapeuticsMD Inc
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Cap:
|
Volume (24h):